Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
dsm-firmenich, has announced a new strategic collaboration with Oz Medicann Group (OMG) Pharma – an Australian-based biotech innovator in the cannabinoid medicines domain – to explore the therapeutic potential of cannabidiol (CBD)-based orally dispersible tablets addressing insomnia.
read more
OncoZenge AB, a pharmaceutical company developing BupiZenge™, a non-opioid based treatment for oral pain, announced that ongoing stability studies for the revised formulation of BupiZenge™ show positive results.
read more
Bora Pharmaceuticals Co., Ltd. announced that it has completed the acquisition of Upsher-Smith Laboratories, a generics manufacturer and marketer based in Minnesota, U.S., from its sellers, Sawai Group Holdings and Sumitomo Corporation of Americas.
read more
Cardinal Health announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of its core pharmaceutical business.
read more
Natural Alternatives International, Inc. announced the expected May 2024 reopening of its state-of-the-art high-volume powder blending and packaging facility located in Carlsbad, CA, following a 7-month closure.
read more
Veranova announced the appointment of Scott Lassonde as Senior Vice President, Chief Financial Officer, signaling a significant milestone in the company's growth and strategic direction.
read more
Bristol Myers Squibb announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease.
read more
CSL Vifor announced that its partner Akebia Therapeutics, Inc. has received FDA approval for Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by ...
read more
Natoli Engineering, the world-renowned leader in tablet compression tooling, presses, machine parts, and encapsulation, is excited to announce the hiring of longtime expert in the field, Todd D. Martin, into his new role as Senior Technical Service Engineer. Prior to his role at Natoli, Mr. Martin served as a Senior Tooling Engineer at Wilson Tool ...
read more
Endo International announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
read more
Viking Therapeutics, Inc. announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic ...
read more
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion.
read more
Hovione, an integrated CDMO and provider of spray drying and particle engineering, and GEA, a provider of process technology for the pharmaceutical industry, announced the next stage of their partnership, with new development agreements, the launch of the ConsiGma® CDC flex as well as the installation of a new lab-scale R&D Continuous Tableting rig...
read more
Journey Medical Corporation announced that the FDA has accepted the Company’s New Drug Application (“NDA”) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults.
read more
The Boehringer Ingelheim Cares Foundation, through its Product Donation Program, has made a significant contribution to animal shelters across the country.
read more